Denise Myshko

Robyn S. Crosson, J.D., VP of government relations at Navitus Health Solutions, has won the PBMI Innovators Award for her work advancing transparency in pharmacy benefits.

PBM reform has finally made its way through Congress and was signed into law by President Donald Trump. Here are seven things you need to know about the law.

Healthcare journalist Ken Terry's new book proposes a subscription-based primary care system as a free-market alternative to Medicare for All.

Additionally, a majority of those surveyed by the law firm DLA Piper were worried about future access to their medications.

Researchers of a systematic review and meta-analysis said there is a need for metabolic and hepatic assessment regardless of weight.

Pasatru is approved to treat adults with fibrodysplasia ossificans progressiva (FOP). It will have an annual list pricing range at launch of $693,000 to $2.1 million, depending on dose and patient weight.

Genglycos is a one-time infusion to replace the G6PC gene in patients with glycogen storage disease type Ia, a rare genetic disorder. It will have a wholesale acquisition cost of $2.7 million per patient.

A deficiency in the hormone GDF15 correlates with liver damage biomarkers, suggesting the hormone may protect against MASH progression and offer a new therapeutic target.

The subcutaneous version of Leqembi has a wholesale acquisition cost of $770 weekly.

Over three years, Advocate Health Care is investing $1 billion in health and wellness initiatives in Chicago, including building a new hospital, expanded outpatient services and new workforce development initiatives.